Whistler, British Columbia, Canada-Intravesical hyaluronic acid (Cystistat) appears to be a simple, quick therapy for reducing pain, frequency, and nocturia in patients with interstitial cystitis, according to Austrian and Canadian researchers. The agent may also improve radiation-induced cystitis and reduce bacterial cystitis recurrences in patients with recurrent urinary tract infections, said Marc Riviere, MD, senior vice president at Belleville, Ontario-based Bioniche Life Sciences Inc., who presented a series of pilot studies at the Canadian Urological Association annual meeting.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
Experts develop guide on online tools to reduce costs of urologic drugs
April 22nd 2024"At a time when patients are increasingly concerned about prescription drugs, this information will provide a useful starting point for making essential medications as affordable as possible," says Ruchika Talwar, MD.